Pharmalot By Ed Silverman How much longer will Gilead wait before buying its way out of the doldrums?
Pharmalot By Ed Silverman Which drug makers do a good job getting poor patients access to their medicines?
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Alkermes depression drug now looks promising, but will FDA bite?
Pharmalot By Ed Silverman Less than 1 percent of state prisoners with hepatitis C get treated due to drug costs
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: North Korea’s Neo-Viagra has the same ingredient as the real thing
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Gilead’s preventive HIV pill must be covered in England
Pharmalot By Ed Silverman Gilead hep C drug prices blamed for England’s health service rationing treatment
Pharmalot By Ed Silverman As hep C sales decline, Wall Street wonders what Gilead does for its next act